Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.admin2020-05-12T17:03:17+00:00May 12th, 2020|Categories: Press Releases|Tags: ADMIRAL, AML, Astellas, Australia, CE-Marked, China, Clinical Trials, Companion Diagnostics, Europe, FLT3 biomarker, Germany, gilteritinib, Invivoscribe, Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd., ITD, Japan, LabPMM, LeukoStrat® CDx FLT3 Mutation Assay, NMPA, QuANTUM-R, RATIFY, refractory FLT3-mutated AML, relapsed FLT3-mutated AML., Rydapt®, Shanghai, Switzerland, TKD, United States, VANFLYTA®, Xospata®| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] > Read More
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesadmin2019-07-04T21:09:04+00:00May 21st, 2019|Categories: Press Releases|Tags: China, Germany, Hematologic Malignancies, Japan, LabPMM, US| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] > Read More
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2019-07-04T21:29:37+00:00March 28th, 2016|Categories: Press Releases|Tags: FLT3, FLT3 Patent, Germany| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] > Read More
